F2G and Shionogi Present Full Data Set from Pivotal Phase 2b Study at Trends in Medical Mycology (TIMM) 2023 Demonstrating Positive Therapeutic Responses in Patients with Invasive Fungal Infections Treated with Oral Olorofim
October 21, 2023 08:30 ET
|
F2G, Ltd.
An overall success rate of 28.7% was seen at day 42, the primary endpoint, and 27.2% at day 84, as determined by a data review committee (DRC) using the EORTC-MSG criteriaThe success rate rose to...
F2G Receives Complete Response Letter from FDA for New Drug Application for Olorofim for The Treatment of Invasive Fungal Infections; Plans Resubmission With Additional Data and Analyses
June 19, 2023 07:30 ET
|
F2G, Ltd.
Complete Response Letter is related to the request for additional data and analyses.F2G remains committed to bringing olorofim to patients and intends to meet with FDA in the coming months to align on...
UPDATE – F2G Wins Investment Deal of the Year Bionow 2022 Award
March 17, 2023 08:45 ET
|
F2G, Ltd.
MANCHESTER, United Kingdom, March 17, 2023 (GLOBE NEWSWIRE) -- F2G Ltd. today announced the company has been awarded a prestigious Bionow award in recognition of its contributions to the North...
F2G Wins Investment Deal of the Year Bionow 2022 Award
March 17, 2023 07:30 ET
|
F2G, Ltd.
MANCHESTER, United Kingdom, March 17, 2023 (GLOBE NEWSWIRE) -- F2G Ltd. today announced the company has been awarded a prestigious Bionow award in recognition of its contributions to the North...
F2G to Present at Biotech Showcase™ 2023
January 05, 2023 07:30 ET
|
F2G, Ltd.
MANCHESTER, United Kingdom, Jan. 05, 2023 (GLOBE NEWSWIRE) -- F2G Ltd. today announced that the Company’s chief executive officer, Francesco Lavino will provide a corporate overview at Biotech...
F2G Announces FDA Filing Acceptance of New Drug Application for Olorofim for the Treatment of Invasive Fungal Infections
December 19, 2022 03:00 ET
|
F2G, Ltd.
Application submitted under priority review with PDUFA target action date set for June 17, 2023NDA submission is based on positive data from ongoing Phase 2b open-label study of oral olorofim in 100...
F2G Announces Data from Phase 2b Study at ID Week 2022 Showing Positive Therapeutic Response in Patients with Invasive Fungal Infections Treated with Olorofim
October 21, 2022 11:30 ET
|
F2G, Ltd.
Data are based on analysis of the first 100 patients from an ongoing Phase 2b study of patients who have limited or no treatment options for invasive fungal infectionsOverall, a 44% response rate,...
F2G to Present Interim Results from Phase 2B Open Label Study of Olorofim in Invasive Fungal Infections at IDWeek 2022
October 13, 2022 10:00 ET
|
F2G, Ltd.
MANCHESTER, United Kingdom, Oct. 13, 2022 (GLOBE NEWSWIRE) -- F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat...